EFGARTIGIMOD ALFA-FCAB (VYVGART®) AND EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC (VYVGART® HYTRULO) PRESCRIBER ORDER FORM





Appleton and Oak Creek, WI

Fax completed form, insurance information, and clinical documentation to:

t 800-648-8055 f 414-563-0600

| Patient Name | | | | Date of Birth: | | | |
|---|-----------------|-------------|--------------|-----------------|---------|-----------|--|
| Patient Name: | | | | Date of Birtii. | | | |
| Address: | | | | | | | |
| Phone: | H | eight: | ☐ inches ☐ d | cm | Weight: | □lbs □ kg | |
| CLINICAL INFORMATION | | | | | | | |
| Primary Diagnosis Description: | | | | ICD-10 Code: | | | |
| PRESCRIPTION | | | | | | | |
| □ VYVGART® (efgartigimod alfa-fcab) 400mg in 20mL • Infuse 10 mg/kg IV over one (1) hour every week x 4 weeks for 1 treatment cycle • Max 1200mg dose for patients >120kg • Using a 50 mL NS IV bag, flush IV tubing with NS 10 to 20 mL after each infusion • Infuse via 0.2 micron in-line filter • Dispense quantity sufficient of 400mg single dose vials for each dose. Round calculated dose to nearest 20mg • Withdraw calculated dose from vial and discard any unused vial contents. □ VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) 1008mg/11,200 units in 5.6mL • Infuse Subcutaneously over 30-90 seconds every week x 4 weeks for 1 treatment cycle • Administer using a winged 25G 12in tubing (maximum priming volume of 0.4 mL) • Dispense 1008mg/11,200 units Repeat cycle after off-weeks. Refill x 1 year. Additional Vyvgart orders: | | | | | | | |
| ANCH LARY ORDERS | | | | | | | |
| ANCILLARY ORDERS | | | | | | | |
| Anaphylaxis Kit Dosage: • Epinephrine 0.3 mg (> 30 kg), 0.15 mg (15 to 30 kg), or 0.01 mg/kg (< 15 kg) SQ or IM x 1; repeat x 1 in 5 to 15 min PRN. • Diphenhydramine 25mg PO or IV/IM. May repeat additionally 25mg PO or IV PRN. • Normal saline 500 mL (> 30 kg) or 250 mL (< 30 kg) IV at KVO rate PRN anaphylaxis. Patient < 30 kg, infuse over 2 to 4 hours PRN headache rated > 5 on pain scale. Pre-Medication Orders □ Other: IV Flush Orders □ Peripheral: NS 2 to 3 mL pre-/post-use. | | | | | | | |
| ☐ Implanted Port: NS 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use. For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed. ☐ Other: | | | | | | | |
| LAB ORDERS | | | | | | | |
| □ No labs ordered at this time. □ Other: Skilled nurse to initiate IV access for administration of doses in the home or alternate care setting. Access to be discontinued upon completion of infusion. Refill above ancillary orders as directed x 1 year. | | | | | | | |
| I certify that the use of the indicated treatment is medically necessary and I will be supervising the patient's treatment. | | | | | | | |
| Prescriber Signature: | | | | _ Date | Date: | | |
| PRESCRIBER INFORMATION | | | | | | | |
| Prescriber Name: | | Phone: Fax: | | | | | |
| Address: | | NPI: | | | | | |
| City, State: | Office Contact: | | | | | | |
| | | | | | | | |

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.